Vericel Director Robert Zerbe Receives Equity Awards and Vested RSUs

This Form 4 filing reports equity transactions for Robert L. Zerbe MD, a director of Vericel Corporation. On April 29, 2026, Zerbe received multiple equity awards: 8,000 stock options with an exercise price of $33.43 per share and 3,200 restricted stock units (RSUs) that vest on April 29, 2027. Additionally, 3,200 RSUs granted on April 30, 2025 vested on April 29, 2026, resulting in the acquisition of 3,200 common shares at $0 cost. Following these transactions, Zerbe holds 32,995 common shares directly, 3,200 unvested RSUs, and 8,000 stock options. The stock options vest monthly over one year contingent on continued service, while the RSUs vest either on specific dates or at the first annual meeting following those dates. The filing demonstrates ongoing equity compensation for Vericel's board members.